The ageing male reproductive tract

Journal of Pathology

Volumn 211, Issue 2, 2007, Pages 206-218

  Sampson, N ^a   Untergasser, G ^b   Plas, E ^c   Berger, Peter ^a  

^a ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c GENERAL HOSPITAL LINZ   (Austria)

Author keywords

Erectile dysfunction; Fertility; Hyperplasia; Prostate; Testis; Testosterone

Indexed keywords

AGENTS ACTING ON THE GENITAL SYSTEM; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIANDROGEN; PHOSPHODIESTERASE V INHIBITOR; SEX HORMONE; SILDENAFIL; TADALAFIL; VARDENAFIL;

AGING; ATHEROSCLEROSIS; CANCER RISK; CELL INTERACTION; CLINICAL FEATURE; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG MECHANISM; EPITHELIUM CELL; ERECTILE DYSFUNCTION; GENE MUTATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GERIATRIC DISORDER; HISTOPATHOLOGY; HORMONE ACTION; HUMAN; HYPERTENSION; HYPOGONADISM; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; MALE; MALE GENITAL SYSTEM DISEASE; MALE INFERTILITY; MUTATIONAL ANALYSIS; PATHOPHYSIOLOGY; PRECANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEMEN ANALYSIS; TESTIS DISEASE; UNSPECIFIED SIDE EFFECT;

AGING; CHRONIC DISEASE; EPITHELIAL CELLS; GENITALIA, MALE; GONADAL STEROID HORMONES; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; IMPOTENCE; MALE; NEUROSECRETORY SYSTEMS; PENIS; PROSTATE; PROSTATIC DISEASES; PROSTATITIS; REPRODUCTION; SPERMATOZOA; TESTIS;

EID: 33846687777     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2077     Document Type: Review

References (184)

1. Kirkwood TB. Understanding the odd science of aging. Cell 2005;120:437-447.
2. Kirkwood TB, Austad SN. Why do we age? Nature 2000;408:233-238.
3. Hermann M, Berger P. Hormonal changes in aging men: a therapeutic indication? Exp Gerontol 2001;36:1075-1082.
4. Bakshi S, Miller DK. Assessment of the aging man. Med Clin North Am 1999;83:1131-1149.
5. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005;26:833-876.
6. Hermann M, Berger P. Hormone replacement in the aging male? Exp Gerontol 1999;34:923-933.
7. Dunbar N, Gruman C, Reisine S, Kenny AM. Comparison of two health status measures and their associations with testosterone levels in older men. Aging Male 2001;4:1-7.
8. Spetz AC, Fredriksson MG, Hammar ML. Hot flushes in a male population aged 55, 65, and 75 years, living in the community of Linkoping, Sweden. Menopause 2003;10:81-87.
9. T'Sjoen G, Goemaere S, De Meyere M, Kaufman JM. Perception of males' aging symptoms, health and well-being in elderly community-dwelling men is not related to circulating androgen levels. Psychoneuroendocrinology 2004;29:201-214.
10. Hermann M, Untergasser G, Rumpold H, Berger P. Ageing of the male reproductive system. Exp Gerontol 2000;35:1267-1279.
11. Deslypere JP, Vermeulen A. Leydig cell function in normal men: effect of age, life-style, residence, diet, and activity. J Clin Endocrinol Metab 1984;59:955-962.
12. Vermeulen A, Kaufman JM, Giagulli VA. Influence of some biological indexes on sex hormone-binding globulin and androgen levels in aging or obese males. J Clin Endocrinol Metab 1996;81:1821-1826.
13. Field AE, Colditz GA, Willett WC, Longcope C, McKinlay JB. The relation of smoking, age, relative weight, and dietary intake to serum adrenal steroids, sex hormones, and sex hormone-binding globulin in middle-aged men. J Clin Endocrinol Metab 1994;79:1310-1316.
14. Key TJ, Roe L, Thorogood M, Moore JW, Clark GM, Wang DY. Testosterone, sex hormone-binding globulin, calculated free testosterone, and oestradiol in male vegans and omnivores. Br J Nutr 1990;64:111-119.
15. Longcope C, Feldman HA, McKinlay JB, Araujo AB. Diet and sex hormone-binding globulin. J Clin Endocrinol Metab 2000;85:293-296.
16. Pfeilschifter J, Scheidt-Nave C, Leidig-Bruckner G, Woitge HW, Blum WF, Wuster C, et al. Relationship between circulating insulin-like growth factor components and sex hormones in a population-based sample of 50-80 year-old men and women. J Clin Endocrinol Metab 1996;81:2534-2540.
17. Stepan JJ, Lachman M, Zverina J, Pacovsky V, Baylink DJ. Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. J Clin Endocrinol Metab 1989;69:523-527.
18. Stoch SA, Parker RA, Chen L, Bubley G, Ko YJ, Vincelette A, et al. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab 2001;86:2787-2791.
19. Khaw KT, Barrett-Connor E. Lower endogenous androgens predict central adiposity in men. Ann Epidemiol 1992;2:675-682.
20. Tenover JS. Androgen administration to aging men. Endocrinol Metab Clin North Am 1994;23:877-892.
21. Yaffe K, Lui LY, Zmuda J, Cauley J. Sex hormones and cognitive function in older men. J Am Geriatr Soc 2002;50:707-712.
22. Moffat SD, Zonderman AB, Metter EJ, Blackman MR, Harman SM, Resnick SM. Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men. J Clin Endocrinol Metab 2002;87:5001-5007.
23. Barrett-Connor E. Testosterone, HDL-cholesterol and cardiovascular disease. In Pharmacology, Biology and Clinical Applications of Androgens: Current Status and Future Prospects, Bhasin S, Gabelnick HC, Spieler JM, Swerdloff RS, Wang C, Kelly C (eds). Wiley-Liss: New York, 1996; 215-223.
24. English KM, Mandour O, Steeds RP, Diver MJ, Jones TH, Channer KS. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J 2000;21:890-894.
25. Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 2002;87:589-598.
26. Schatzl G, Madersbacher S, Temml C, Krenn-Schinkel K, Nader A, Sregi G, et al. Serum androgen levels in men: impact of health status and age. Urology 2003;61:629-633.
27. Madersbacher S, Stulnig T, Huber LA, Schonitzer D, Dirnhofer S, Wick G, et al. Serum glycoprotein hormones and their free alpha-subunit in a healthy elderly population selected according to the SENIEUR protocol. Analyses with ultrasensitive time resolved fluoroimmunoassays. Mech Ageing Dev 1993;71:223-233.
28. Keenan DM, Takahashi PY, Liu PY, Roebuck PD, Nehra AX, Iranmanesh A, et al. An ensemble model of the male gonadal axis: illustrative application in aging men. Endocrinology 2006;147:2817-2828.
29. Neaves WB, Johnson L, Porter JC, Parker CR Jr, Petty CS. Leydig cell numbers, daily sperm production, and serum gonadotropin levels in aging men. J Clin Endocrinol Metab 1984;59:756-763.
30. Johnson L. Spermatogenesis and aging in the human. J Androl 1986;7:331-354.
31. Suoranta H. Changes in the small blood vessels of the adult human testis in relation to age and to some pathological conditions. Virchows Arch A Pathol Pathol Anat 1971;352:165-181.
32. Takahashi J, Higashi Y, LaNasa JA, Yoshida K, Winters SJ, Oshima H, et al. Studies of the human testis. XVIII. Simultaneous measurement of nine intratesticular steroids: evidence for reduced mitochondrial function in testis of elderly men. J Clin Endocrinol Metab 1983;56:1178-1187.
33. Harman SM, Tsitouras PD. Reproductive hormones in aging men. I. Measurement of sex steroids, basal luteinizing hormone, and Leydig cell response to human chorionic gonadotropin. J Clin Endocrinol Metab 1980;51:35-40.
34. Wang X, Shen CL, Dyson MT, Eimerl S, Orly J, Hutson JC, et al. Cyclooxygenase-2 regulation of the age-related decline in testosterone biosynthesis. Endocrinology 2005;146:4202-4208.
35. Bergendahl M, Aloi JA, Iranmanesh A, Mulligan TM, Veldhuis JD. Fasting suppresses pulsatile luteinizing hormone (LH) secretion and enhances orderliness of LH release in young but not older men. J Clin Endocrinol Metab 1998;83:1967-1975.
36. Kidd SA, Eskenazi B, Wyrobek AJ. Effects of male age on semen quality and fertility: a review of the literature. Fertil Steril 2001;75:237-248.
37. Kuhnert B, Nieschlag E. Reproductive functions of the ageing male. Hum Reprod Update 2004;10:327-339.
38. Plas E, Berger P, Hermann M, Pfluger H. Effects of aging on male fertility? Exp Gerontol 2000;35:543-551.
39. Auger J, Kunstmann JM, Czyglik F, Jouannet P. Decline in semen quality among fertile men in Paris during the past 20 years. N Engl J Med 1995;332:281-285.
40. Eskenazi B, Wyrobek AJ, Sloter E, Kidd SA, Moore L, Young S, et al. The association of age and semen quality in healthy men. Hum Reprod 2003;18:447-454.
41. Rolf C, Kenkel S, Nieschlag E. Age-related disease pattern in infertile men: increasing incidence of infections in older patients. Andrologia 2002;34:209-217.
42. Rolf C, Behre HM, Nieschlag E. Reproductive parameters of older compared to younger men of infertile couples. Int J Androl 1996;19:135-142.
43. Nieschlag E, Lammers U, Freischem CW, Langer K, Wickings EJ. Reproductive functions in young fathers and grandfathers. J Clin Endocrinol Metab 1982;55:676-681.
44. Haidl G, Jung A, Schill WB. Ageing and sperm function. Hum Reprod 1996;11:558-560.
45. Hassan MA, Killick SR. Effect of male age on fertility: evidence for the decline in male fertility with increasing age. Fertil Steril 2003;79(suppl 3):1520-1527.
46. Seftel AD. Erectile dysfunction in the elderly: epidemiology, etiology and approaches to treatment. J Urol 2003;169:1999-2007.
47. O'Donnell AB, Aranjo AB, McKinlay JB. The health of normally aging men: the Massachusetts Male Aging Study (1987-2004). Exp Gerontol 2004;39:975-984.
48. Kloner RA. Erectile dysfunction in the cardiac patient. Curr Urol Rep 2003;4:466-471.
49. Richardson D, Vinik A. Etiology and treatment of erectile failure in diabetes mellitus. Curr Diab Rep 2002;2:501-509.
50. Montorsi F, Burnett AL. Erectile dysfunction after radical prostatectomy. BJU Int 2004;93:1-2.
51. Wespes E. The ageing penis. World J Urol 2002;20:36-39.
52. Rosen RC, Kostis JB. Overview of phosphodiesterase 5 inhibition in erectile dysfunction. Am J Cardiol 2003;92:9M-18M.
53. Wespes E. Erectile dysfunction in the ageing man. Curr Opin Urol 2000;10:625-628.
54. Mikhail N. Does testosterone have a role in erectile function? Am J Med 2006;119:373-382.
55. Schneider T, Sperling H, Lummen G, Syllwasschy J, Rubben H. Does penile size in younger men cause problems in condom use? A prospective measurement of penile dimensions in 111 young and 32 older men. Urology 2001;57:314-318.
56. Gonzalez-Cadavid NF, Rajfer J. Molecular pathophysiology and gene therapy of aging-related erectile dysfunction. Exp Gerontol 2004;39:1705-1712.
57. Tokar EJ, Ancrile BB, Cunha GR, Webber MM. Stem/progenitor and intermediate cell types and the origin of human prostate cancer. Differentiation 2005;73:463-473.
58. Peehl DM. Primary cell cultures as models of prostate cancer development. Endocr Relat Cancer 2005;12:19-47.
59. Long RM, Morrissey C, Fitzpatrick JM, Watson RW. Prostate epithelial cell differentiation and its relevance to the understanding of prostate cancer therapies. Clin Sci 2005;108:1-11.
60. Hermann M, Untergasser G, Rumpold H, Berger P. Ageing of the male reproductive system. Exp Gerontol 2000;35:1267-1279.
61. Isaacs JT. Etiology of benign prostatic hyperplasia. Eur Urol 1994;25:6-9.
62. De Marzo AM, Coffey DS, Nelson WG. New concepts in tissue specificity for prostate cancer and benign prostatic hyperplasia. Urology 1999;53:29-39.
63. Steiner MS, Couch RC, Raghow S, Stauffer D. The chimpanzee as a model of human benign prostatic hyperplasia. J Urol 1999;162:1454-1461.
64. Untergasser G, Madersbacher S, Berger P. Benign prostatic hyperplasia: age-related tissue-remodeling. Exp Gerontol 2005;40:121-128.
65. Bonkhoff H, Remberger K. Morphogenetic concepts of normal and abnormal growth in the human prostate. Virchows Archiv 1998;433:195-202.
66. Bedford MT, van Helden PD. Hypomethylation of DNA in pathological conditions of the human prostate. Cancer Res 1987;47:5274-5276.
67. Prakash K, Pirozzi G, Elashoff M, Munger W, Waga I, Dhir R, et al. Symptomatic and asymptomatic benign prostatic hyperplasia molecular differentiation by using microarrays. Proc Natl Acad Sci USA 2002;99:7598-7603.
68. Howe HL, Wingo PA, Thun MJ, Ries LAG, Rosenberg HM, Feigal EG, et al. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst 2001;93:824-842.
69. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001;37:S4-S66.
70. Bostwick DG, Qian J. High-grade prostatic intraepithelial neoplasia. Mod Pathol 2004;17:360-379.
71. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003;349:366-381.
72. van Leenders G, Schalken JA. Stem cell differentiation within the human prostate epithelium: implications for prostate carcinogenesis. BJU Int 2001;88(suppl 2):35-42.
73. van Leenders G, Gage WR, Hicks JL, van Balken B, Aalders TW, Schalken JA, et al. Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy. Am J Pathol 2003;162:1529-1537.
74. Schalken JA, van Leenders G. Cellular and molecular biology of the prostate: stem cell biology. Urology 2003;62:11-20.
75. Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea - a paradigm shift. Cancer Res 2006;66:1863-1890.
76. Hill RP. Identifying cancer stem cells in solid tumours: case not proven. Cancer Res 2006;66:1891-1896.
77. Rizzo S, Attard G, Hudson DL. Prostate epithelial stem cells. Cell Prolif 2005;38:363-374.
78. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumourigenic prostate cancer stem cells. Cancer Res 2005;65:10946-10951.
79. Tomlins SC, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun X-W, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-648.
80. Hughes C, Murphy A, Martin C, Sheils O, O'Leary J. Molecular pathology of prostate cancer. J Clin Pathol 2005;58:673-684.
81. Ribeiro FR, Diep CB, Jeronimo C, Henrique R, Lopes C, Eknaes M, et al. Statistical dissection of genetic pathways involved in prostate carcinogenesis. Genes Chromosomes Cancer 2006;45:154-163.
82. Schulz WA, Hatina J. Epigenetics of prostate cancer: beyond DNA methylation. J Cell Mol Med 2006;10:100-125.
83. Zhang Z, Karam J, Frenkel E, Sagalowsky A, Hsieh J-T. The application of epigenetic modifiers on the treatment of prostate and bladder cancer. Urol Oncol 2006;24:152-160.
84. Kirschenbaum A, Liu XH, Yao S, Narla G, Friedman SL, Martignetti JA, et al. Sex steroids have differential effects on growth and gene expression in primary human prostatic epithelial cell cultures derived from the peripheral versus transition zones. Carcinogenesis 2006;27:216-224.
85. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001;412:822-826.
86. Nelson PS, Clegg N, Arnold H, Ferguson C, Bonham M, White J, et al. The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci USA 2002;99:11890-11895.
87. DePrimo S, Diehn M, Nelson J, Reiter R, Matese J, Fero M, et al. Transcriptional programs activated by exposure of human prostate cancer cells to androgen. Genome Biol 2002;3:research0032.0031-research0032.0012.
88. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, et al. Gene profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 2004;101:811-816.
89. Shah US, Getzenberg RH. Fingerprinting the diseased prostate: associations between BPH and prostate cancer. J Cell Biochem 2004;91:161-169.
90. Hiramatsu M, Maehara I, Ozaki M, Harada N, Orikasa S, Sasano H. Aromatase in hyperplasia and carcinoma of the human prostate. Prostate 1997;31:118-124.
91. Bonnet P, Reiter E, Bruyninx M, Sente B, Dombrowicz D, de Leval J, et al. Benign prostatic hyperplasia and normal prostate ageing: differences in types I and II 5 alpha-reductase and steroid hormone receptor messenger ribonucleic acid (mRNA) levels, but not in insulin-like growth factor mRNA levels. J Clin Endocrinol Metab 1993;77:1203-1208.
92. Zhang J, Hess MW, Thurnher M, Hobisch A, Radmayr C, Cronauer MV, et al. Human prostatic smooth muscle cells in culture: estradiol enhances expression of smooth muscle cell-specific markers. Prostate 1997;30:117-129.
93. Wang Y, Hayward SW, Donjacour AA, Young P, Jacks T, Sage J, et al. Sex hormone-induced carcinogenesis in Rb-deficient prostate tissue. Cancer Res 2000;60:6008-6017.
94. Tam NN, Ghatak S, Ho SM. Sex hormone-induced alterations in the activities of antioxidant enzymes and lipid peroxidation status in the prostate of Noble rats. Prostate 2003;55:1-8.
95. Ricke WA, Ishii K, Ricke EA, Simko J, Wang Y, Hayward SW, et al. Steroid hormones stimulate human prostate cancer progression and metastasis. Int J Cancer 2006;118:2123-2131.
96. Soronen P, Laiti M, Törn S, Härkonen P, Patrikainen L, Li Y, et al. Sex steroid hormone metabolism and prostate cancer. J Steroid Biochem Mol Biol 2004;92:281-286.
97. Pylkkanen L, Santti R, Salo L, Maentausta O, Vihko R, Nurmi M. Immunohistochemical localisation of oestrogen-specific 17 beta-hydroxysteroid oxidoreductase in the human and mouse prostate. Prostate 1994;25:292-300.
98. Fung KM, Samara EN, Wong C, Metwalli A, Krlin R, Bane B, et al. Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma. Endocr Relat Cancer 2006;13:169-180.
99. Tang W, Norlin M. Regulation of steroid hydroxylase CYP7B1 by androgens and estrogens in prostate cancer LNCaP cells. Biochem Biophys Res Commun 2006;344:540-546.
100. Ellem SJ, Schmitt JF, Pedersen JS, Frydenberg M, Risbridger GP. Local aromatase expression in human prostate is altered in malignancy. J Clin Endocrinol Metab 2004;89:2434-2441.
101. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006;66:2815-2825.
102. Harkonen PL, Makela SI. Role of estrogens in development of prostate cancer. J Steroid Biochem Mol Biol 2004;92:297-305.
103. Harkonen P, Torn S, Kurkela R, Porvari K, Pulkka A, Lindfors A, et al. Sex hormone metabolism in prostate cancer cells during transition to an androgen-independent state. J Clin Endocrinol Metab 2003;88:705-712.
104. Hatzoglou A, Kampa M, Kogia C, Charalampopoulos I, Theodoropoulos PA, Anezinis P, et al. Membrane androgen receptor activation induces apoptotic regression of human prostate cancer cells in vitro and in vivo. J Clin Endocrinol Metab 2005;90:893-903.
105. Taylor RA, Cowin P, Couse JF, Korach KS, Risbridger GP. 17beta-Estradiol induces apoptosis in the developing rodent prostate independently of ERalpha or ERbeta. Endocrinology 2006;147:191-200.
106. Freeman MR, Cinar B, Lu ML. Membrane rafts as potential sites of nongenomic hormonal signaling in prostate cancer. Trends Endocrinol Metab 2005;16:273-279.
107. Tsurusaki T, Aoki D, Kanetake H, Inoue S, Muramatsu M, Hishikawa Y, et al. Zone-dependent expression of estrogen receptors alpha and beta in human benign prostatic hyperplasia. J Clin Endocrinol Metab 2003;88:1333-1340.
108. Leav I, Lau KM, Adams JY, McNeal J, Taplin ME, Wang JP, et al. Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia and in primary and metastatic carcinoma. Am J Pathol 2001;159:79-92.
109. Prins GS, Jung MH, Vellanoweth RL, Chatterjee B, Roy AK. Age-dependent expression of the androgen receptor gene in the prostate and its implication in glandular differentiation and hyperplasia. Dev Genet 1996;18:99-106.
110. Garraway LA, Lin D, Signoretti S, Waltregny D, Dilks J, Bhattacharya N, et al. Intermediate basal cells of the prostate: in vitro and in vivo characterization. Prostate 2003;55:206-218.
111. Banerjee PP, Banerjee S, Brown TR. Increased androgen receptor expression correlates with development of age-dependent, lobe-specific spontaneous hyperplasia of the brown Norway rat prostate. Endocrinology 2001;142:4066-4075.
112. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006;66:2815-2825.
113. Culig Z, Comuzzi B, Steiner H, Bartsch G, Hobisch A. Expression and function of androgen receptor coactivators in prostate cancer. J Steroid Biochem Mol Biol 2004;92:265-271.
114. Li W, Cavasotto CN, Cardozo T, Ha S, Dang T, Taneja SS, et al. Androgen receptor mutations identified in prostate cancer and androgen insensitivity syndrome display aberrant ART-27 coactivator function. Mol Endocrinol 2005;19:2273-2282.
115. Agoulnik IU, Vaid A, Bingman WEr, Erdeme H, Frolov A, Smith CL, et al. Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res 2005;65:7959-7967.
116. Hendriksen PJM, Dits NFJ, Kokame K, Veldhoven A, van Weerden WM, Bangma CH, et al. Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Res 2006;66:5012-5020.
117. Dehm SM, Tindall DJ. Molecular recognition of androgen action in prostate cancer. J Cell Biochem 2006;epub.
118. Bektic J, Wrulich OA, Dobler G, Kofler K, Ueberall F, Culig Z, et al. Identification of genes involved in estrogenic action in the human prostate using microarray analysis. Genomics 2004;83:34-44.
119. Salm SN, Burger PE, Coetzee S, Goto K, Moscatelli D, Wilson EL. TGF-β maintains dormancy of prostatic stem cells in the proximal region of ducts. J Cell Biol 2005;170:81-90.
120. Kang HY, Huang KE, Chang SY, Ma WL, Lin WJ, Chang C. Differential modulation of androgen receptor-mediated transactivation by Smad3 and tumor suppressor Smad4. J Biol Chem 2002;277:43749-43756.
121. van Dev Poel HG. Androgen receptor and TGFbeta1/Smad signaling are mutually inhibitory in prostate cancer. Eur Urol 2005;48:1051-1058.
122. Carey JL, Sasur LM, Kawakubo H, Gupta V, Christian B, Bailey PM, et al. Mutually antagonistic effects of androgen and activin in the regulation of prostate cancer cell growth. Mol Endocrinol 2004;18:696-707.
123. Brodin G, ten Dijke P, Funa K, Heldin CH, Landstrom M. Increased smad expression and activation are associated with apoptosis in normal and malignant prostate after castration. Cancer Res 1999;59:2731-2738.
124. Bruckheimer EM, Kyprianou N. Bcl-2 antagonises the combined apoptotic effect of transforming growth factor beta and dihydrotestosterone in prostate cancer cells. Prostate 2002;53:133-142.
125. Kyprianou N, Tu H, Jacobs SC. Apoptotic versus proliferative activities in human benign prostatic hyperplasia. Hum Pathol 1996;27:668-675.
126. Shariat SF, Ashfaq R, Roehrborn C, Slawin KM, Lotan Y. Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia. J Urol 2005;174:2046-2050.
127. Royuela M, Arenas MI, Bethencourt FR, Sanchez-Chapado M, Fraile B, Paniagua R. Regulation of proliferation/apoptosis equilibrium by mitogen-activated protein kinases in normal, hyperplastic, and carcinomatous human prostate. Hum Pathol 2002;33:299-306.
128. Cordon-Cardo C, Koff A, Drobnjak M, Capodieci P, Osman I, Millard SS, et al. Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J Natl Cancer Inst 1998;90:1284-1291.
129. Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD, Rowley DR. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodelling. Clin Cancer Res 2002;8:2912-2923.
130. Rumpold H, Untergasser G, Madersbacher S, Berger P. The development of benign prostatic hyperplasia by trans-differentiation of prostatic stromal cells. Exp Gerontol 2002;37:1001-1004.
131. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005;121:335-348.
132. Hill R, Song Y, Cardiff RD, Van Dyke T. Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell 2005;123:1001-1011.
133. Kiaris H, Chatzistamou I, Trimis G, Frangous-Plemmenous M, Pafiti-Kondi A, Kalofoutis A. Evidence for nonautonomous effect of p53 tumor suppressor in carcinogenesis. Cancer Res 2005;65:1627-1630.
134. Pandini G, Mineo R, Frasca F, Roberts CT, Marcelli M, Vigneri R, et al. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells. Cancer Res 2005;65:1849-1857.
135. Le H, Arnold JT, McFann KK, Blackman MR. DHT and testosterone but not DHEA or E2 differentially modulate IGF-I, IGFBP-2 and IGFBP-3 in human prostatic stromal cells. Am J Physiol Endocrinol Metab 2006;290:E952-E960.
136. Wu JD, Haugk K, Woodke L, Nelson PS, Coleman I, Plymate S. Interaction of IGF signaling and the androgen receptor in prostate cancer progression. J Cell Biochem 2006;25:epub.
137. Gennigens C, Menetrier-Caux C, Droz JP. Insulin-like growth factor (IGF) family and prostate cancer. Crit Rev Oncol Hematol 2006;58:124-145.
138. Kawada M, Inoue H, Masuda T, Ikeda D. Insulin-like growth factor I secreted from prostate stromal cells mediates tumor-stromal cell interactions of prostate cancer. Cancer Res 2006;66:4419-4425.
139. Kojima S, Mulholland DJ, Ettinger S, Fazli L, Nelson CC, Gleave ME. Differential regulation of IGFBP-3 by the androgen receptor in the lineage-related androgen-dependent LNCaP and androgen-independent C4-2 prostate cancer models. Prostate 2006;66:971-986.
140. Untergasser G, Gander R, Lilg C, Lepperdinger G, Plas E, Berger P. Profiling molecular targets of TGF-β1 in prostate fibroblast-to-myofibroblast transdifferentiation. Mech Age Dev 2005;126:59-69.
141. Cohen P, Nunn SE, Peehl DM. Transforming growth factor-beta induces growth inhibition and IGF-binding protein-3 production in prostatic stromal cells: abnormalities in cells cultured from benign prostatic hyperplasia tissues. J Endocrinol 2000;164:215-223.
142. Castro P, Giri D, Lamb DJ, Ittmann M. Cellular senescence in the pathogenesis of benign prostatic hyperplasia. Prostate 2003;55:30-38.
143. Dimri GP, Lee X, Basile G, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 1995;92:9363-9367.
144. Krtolica A, Parrinello S, Lockett S, Desprez PY, Campisi J. Senescent fibroblasts promote epithelial cell growth and tumourigenesis: a link between cancer and ageing. Proc Natl Acad Sci USA 2001;98:12072-12077.
145. Parrinello S, Coppe J-P, Krtolica A, Campisi J. Stromal-epithelial interactions in aging and cancer: senescent fibroblasts alter epithelial cell differentiation. J Cell Sci 2005;118:485-496.
146. Bavik C, Coleman I, Dean JP, Knudsen BS, Plymate S, Nelson PS. The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. Cancer Res 2006;66:794-802.
147. Rumpold H, Heinrich E, Untergasser G, Hermann M, Pfister G, Plas E, et al. Neuroendocrine differentiation of human prostatic primary epithelial cells in vitro. Prostate 2002;53:101-108.
148. Berger P, Gruschwitz M, Spoettl G, Dirnhofer S, Madersbacher S, Gerth R, et al. Human chorionic gonadotropin (hCG) in the male reproductive tract. Mol Cell Endocrinol 2007;260-262:190-196.
149. Jongsma J, Oomen MH, Noordzij MA, et al. Androgen-independent growth is induced by neuropeptides in human prostate cancer cell lines. Prostate 2000;42:34-44.
150. Guate JL, Escaf S, Menendez CL, del Valle M, Vega JA. Neuroendocrine cells in benign prostatic hyperplasia and prostatic carcinoma: effect of hormonal treatment. Urol Int 1997;59:149-153.
151. Uchida K, Masumori N, Takahashi A, Itoh N, Kato K, Matusik RJ, et al. Murine androgen-independent neuroendocrine carcinoma promotes metastasis of human prostate cancer cell line LNCaP. Prostate 2006;66:536-545.
152. Xue Y, van Dev Laak J, Smedts F, Schoots C, Verhofstad A, de la Rosette J, et al. Neuroendocrine cells during human prostate development: does neuroendocrine cell density remain constant during fetal as well as postnatal life? Prostate 2000;42:116-123.
153. Cockett AT, di Sant'Agnese PA, Gopinath P, Schoen SR, Abrahamsson PA. Relationship of neuroendocrine cells of prostate and serotonin to benign prostatic hyperplasia. Urology 1993;42:512-519.
154. Untergasser G, Plas E, Pfister G, Heinrich E, Berger P. Interferon-gamma induces neuroendocrine-like differentiation of human prostate basal-epithelial cells. Prostate 2005;64:419-429.
155. Yang X, Chen MW, Terry S, Vacherot F, Chopin DK, Bemis DL, et al. A human- and male-specific protocadherin that acts through the wnt signaling pathway to induce neuroendocrine transdifferentiation of prostate cancer cells. Cancer Res 2005;65:5263-5271.
156. Humez S, Monet M, Legrand G, Lepage G, Delcourt P, Prevarskaya N. Epidermal growth factor-induced neuroendocrine differentiation and apoptotic resistance of androgen-independent human prostate cancer cells. Endocr Relat Cancer 2006;14:181-195.
157. Mosca A, Berruti A, Russo L, Torta M, Dogliotti L. The neuroendocrine phenotype in prostate cancer: basic and clinical aspects. J Endocrinol Invest 2005;28:141-145.
158. Nelson WG, De Marzo AM, DeWeese TL, Isaacs WB. The role of inflammation in the pathogenesis of prostate cancer. J Urol 2004;172:S6-11; discussion S11-12.
159. Palapattu GS, Sutcliffe S, Bastian PJ, Platz EA, De Marzo AM, Isaacs WB, et al. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis 2005;26:1170-1181.
160. Kramer G, Marberger M. Could inflammation be a key component in the progression of benign prostatic hyperplasia? Curr Opin Urol 2006;16:25-29.
161. Chung TD, Yu JJ, Spiotto MT, Bartkowski M, Simons JW. Characterization of the role of IL-6 in the progression of prostate cancer. Prostate 1999;38:199-207.
162. Kramer G, Steiner GE, Handisurya A, Stix U, Haitel A, Knerer B, et al. Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation. Prostate 2002;52:43-58.
163. Zhu P, Baek SH, Bourk EM, Ohgi KA, Garcia-Bassets I, Sanjo H, et al. Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. Cell 2006;124:615-29.
164. Giri D, Ittmann M. Interleukin-8 is a paracrine inducer of fibroblast growth factor 2, a stromal and epithelial growth factor in benign prostatic hyperplasia. Am J Pathol 2001;159:139-147.
165. Robinette CL. Sex-hormone induced inflammation and fibromuscular proliferation in the rat lateral prostate. Prostate 1988;12:271-286.
166. Asirvatham AJ, Schmidt M, Gao B, Chaudhary J. Androgens regulate the immune/inflammatory response and cell survival pathways in rat ventral prostate epithelial cells. Endocrinology 2006;147:257-271.
167. Schwartz GG. Vitamin D and the epidemiology of prostate cancer. Semin Dial 2005;18:276-289.
168. Norm L, Peng L, Feldman D, Peehl DM. Inhibition of p38 by vitamin D reduces interleukin-6 production in normal prostate cells via mitogen-activated protein kinase phosphatase 5: implications for prostate cancer prevention by vitamin D. Cancer Res 2006;66:4516-4524.
169. Bao BY, Yao J, Lee YF. 1α,25-dihydroxyvitamin D3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis. Carcinogenesis 2006;27:1883-1893.
170. Zhang F, Lee J, Lu S, Pettaway CA, Dong Z. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice. Clin Cancer Res 2005;11:4512-4520.
171. Liu J, Schuff-Werner P, Steiner M. Thrombin/thrombin receptor (PAR-1)-mediated induction of IL-8 and VEGF expression in prostate cancer cells. Biochem Biophys Res Commun 2006;343:183-189.
172. Huang J, Yao JL, Zhang L, Bourne PA, Quinn AM, di Sant'Agnese PA, et al. Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer. Am J Pathol 2005;166:1807-1815.
173. Lu S, Dong Z. Characterization of TGF-beta-regulated interleukin-8 expression in human prostate cancer cells. Prostate 2006;66:996-1004.
174. Castro P, Xia C, Gomez L, Lamb DJ, Ittmann M. Interleukin-8 expression is increased in senescent prostatic epithelial cells and promotes the development of benign prostatic hyperplasia. Prostate 2004;60:153-159.
175. Tarter TH, Vaughan EDJ. Inhibitors of 5alpha-reductase in the treatment of benign prostatic hyperplasia. Curr Pharm Des 2006;12:775-783.
176. Armstrong AJ, Carducci MA. New drugs in prostate cancer. Curr Opin Urol 2006;16:138-145.
177. Bullock TL, Andriole GLJ. Emerging drug therapies for benign prostatic hyperplasia. Expert Opin Emerging Drugs 2006;11:111-123.
178. Bradford TJ, Xiaoju W, Chinnaiyan AM. Cancer immunomics: using autoantibody signatures in the early detection of prostate cancer. Urol Oncol 2006;24:237-242.
179. Small EJ, Roach MR. Prostate-specific antigen in prostate cancer: a case study in the development of a tumour marker to monitor recurrence and assess response. Sem Oncol 2002;29:264-273.
180. Kirby RS, Christmas TJ, Brawer MK. In Prostate Cancer. Mosby: London, 2001.
181. Nanni S, Priolo C, Grasselli A, D'Eletto M, Merola R, Moretti R, et al. Epithelial-restricted gene profile of primary cultures from human
182. True L, Coleman I, Hawley S, Huang CY, Gifford D, Coleman R, et al. A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci USA 2006;103:10991-10996.
183. Craft N, Chhor C, Tran C, Belldegrun A, DeKernion J, Witte ON, et al. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumours through a two-step process. Cancer Res 1999;59:5030-5036.
184. Che M, Grignon D. Pathology of prostate cancer. Cancer Metast Rev 2002;21:381-395.